Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Furkejuvvon:

Bibliográfalaš dieđut
Publikašuvnnas:	Breast Cancer Research vol. 27 (2025), p. 1-16
Váldodahkki:	Hamilton, Erika P
Eará dahkkit:	Patel, Manish R, Borges, Virginia F, Meisel, Jane L, Okera, Meena, Alemany, Carlos A, Pluard, Timothy J, Wesolowski, Robert, Sabanathan, Dhanusha, Miller, Kathy D, Conlin, Alison K, McCarthy, Nicole, Shaw, Morena, Tonda, Margaret, Shilkrut, Mark, Lin, Nancy U
Almmustuhtton:	Springer Nature B.V.
Fáttát:	United States > US Plasma Womens health Metastasis Toxicity Cancer therapies Mutation Antitumor activity Laboratories Breast cancer Metastases Estrogens Kinases Estrogen receptors ErbB-2 protein Endocrine therapy Patients Neutropenia Pharmacokinetics Cyclin-dependent kinases Biomarkers Chemotherapy Tumors Cancer
Liŋkkat:	Citation/Abstract Full Text Full Text - PDF
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!